Table 2 All included studies
Author | Year | Cancer site | No of pts | Pts with tox | OAR studied | Toxicity score used | RT Type | Primary RT Dose (Gy/#) | Pelvic RT dose (Gy/#) | Concurrent chemo use |
Adkison [34] | 2012 | Prostate | 53 | 20 | small bowel | CTCAE v3.0 | IMRT | 70/28 | 56/28 | no |
al-Abany [18] | 2005 | Prostate | 65 | 9 | anal sphincter region | Own questionnaire | 3D | 70.2/39 | NS | no |
Alsadius [19] | 2012 | Prostate or prostatic bed | 403 | 51 | anal sphincter region | Own questionnaire | 3D | 70/35 | NS | no |
Buettner [20] | 2012 | Prostate | 388 | 57 | anal canal | Common grading scheme | 3D | 64/32 or 74/37 | NS | no |
Chopra [11] | 2014 | Cervix (post-op) | 71 | 9 | small bowel, large bowel | CTCAE v3.0 | IG-MRT (46); 3D (25) | 50/25 | 50/25 | 63/71 cisplatin |
Deville [31] | 2010 | Prostate | 30 | 2 | intestinal cavity | RTOG | IMRT | 79.2/44 | 45/25 | no |
Deville [7] | 2012 | Prostatic bed | 36 | 5 | intestinal cavity | RTOG | IMRT | 70.2/39 | 45/25 | no |
Ebert [35] | 2015 | Prostate | 754 | Symptom specific | Anal canal | LENT-SOMA | IMRT | 66–78/33–38 | NS | no |
Fokdal [14] | 2005 | Prostate or bladder | 71 | Symptom specific | small bowel | LENT-SOMA | Conformal | 60/30 (bladder) 69.6/35 (prostate) | 48-60Gy bladder; NS for prostate) | no |
Fonteyne [17] | 2007 | Prostate | 241 | Symptom specific | small bowel, sigmoid | RTOG and “RILIT” | IMRT | 74/37–80/40 | NS | no |
Green [36] | 2015 | Prostate or prostatic bed | 73 | 10 | Intestinal cavity | CTCAE v4.0 | IMRT/VMAT | 61–79.2 | 45 | no |
Guerrero- Urbano [8] | 2010 | Prostate & Pelvic nodes | 79 | 21 | bowel loops | RTOG diarrhoea & LENT SOMA diarrhoea | IMRT | 70/35 | 50/35 or 55/35 | no |
Huang [15] | 2011 | Pancreas | 46 | 8 | duodenum | CTCAE v4.0 | 3D or IMRT | 42/15 | 42/15; 36/15; 38/19 | Gemcitabine; 18 pts. erlotinib in addition |
Isohashi [10] | 2013 | Cervix (post-op) | 97 | 16 | peritoneal cavity, small and large bowel | RTOG/EORTC | 2D or 3D | 50/25 | 50/25 | All nedaplatin |
Kelly [13] | 2013 | Pancreas | 106 | 20 | duodenum | CTCAE v4.0 | 3D or IMRT | 50.4/28 (78pts); 57.5–75.4 in 28–39# (28pts) | 50.4/28 (78pts); 57.5–75.4 in 28–39# (28pts) | Gemcitabine 5-FUor capecitabine +/− cetuximab or erlotinib |
Author | Year | Cancer site | No of pts | Pts with tox | OAR studied | Toxicity score used | RT Type | RT Dose (Gy/#) | Pelvic RT dose (Gy/#) | Concurrent chemo use |
Koper [25] | 2004 | Prostate | 266 | 141 | anal canal | RTOG (simplified) Symptom questionnaire | 3D or 2D | 66/33 | NS | no |
Lind [12] | 2016 | Cervical or Endometrium | 519 | 63 | Anal sphincter, small bowel, sigmoid | Own questionnaire (defecation into clothing without forewarning) | 2D or 3D | 40–46 (endometrium) or 55–70 (cervix) | NS | Not stated |
Mavroidis [27] | 2005 | Prostate | 65 | Symptom specific | anal sphincter | Own questionnaire | 3D | 70.2/39 | NS | no |
Mcdonald [9] | 2015 | Bladder | 47 | 10 | bowel loops | RTOG | 3D | 64/32 | 64/32 | 21 received 5-FU/MMC |
Mouttet-Audouard [6] | 2015 | Cervical | 37 | 8 | Small bowel [defined as peritoneal cavity], sigmoid | CTCAE v4.0 | IMRT (tomotherapy) | 60/28 | 50/28 | Cisplatin |
Peeters [21] | 2006 | Prostate | 641 | 146 | Anal wall | RTOG/EORTC plus 5 specified symptoms | 3D (41 pts. had IMRT boost) | 68/34 or 78/39 | NS | no |
Peeters [28] | 2006 | Prostate | 368 | 32 | Anal wall | Incontinence (no specific questionnaire) | 3D (22 pts. had boost) | 68/34 or 78/39 | NS | no |
Poorvu [16] | 2013 | Cervix or Endometrium (+ PA nodes) | 46 | 3 | peritoneal cavity, small bowel, duodenal segments | CTCAE v4.0 | IMRT | 45/25 (22pts); PAN boost 50–65 (33pts) | 45/25 & PAN boost 50–65 (33 pts) | 24 received cisplatin |
Smeenk [26] | 2012 | Prostate | 48 | 21 | Anal sphincter muscles | Presence of frequency, urgency and incontinence | 3D (n = 43, IMRT (n = 5) | 67.5/27 or 70/28 | NS | no |
Smeenk [22] | 2012 | Prostate | 36 | 23 | Anal wall | Late RILIT score: urgency, incontinence, frequency | 3D | 67.5/27 or 70/28 | NS | no |
Taussky [37] | 2003 | Prostate | 73 | unclear | anal canal | UCLA, FACT-P and EORTC QLQ-PR25 | 3D | 66.6–72/ 37–40 | NS | no |
Thor [29] | 2015 | Prostate | 212 | Symptom specific | Anal sphincter | Own questionnaire with 19 descriptors for 4 symptoms | 3D | 70-78Gy | NS | no |
Verma [30] | 2014 | Cervix & Endometrium | 105 | 9 | duodenum | RTOG and endoscopic findings | IMRT | 45–50 (60-66Gy boost) | 45–50 (60–66 boost) | 58 pts. platinum agents |
Vordermark [23] | 2003 | Prostate or prostatic bed | 44 | 14% severe incontinence | anal canal | 10 question continence questionnaire | 3D | 58–72/29–36 | NS | No |
Yeoh [24] | 2016 | Prostate | 106 | 72% | Anal wall | LENT-SOMA total score | 3D | 66–74.4/ 33–4 | NS | no |